John Maraganore
Board Member
Beam Therapeutics Inc. (BEAM)Board Member
Kymera Therapeutics, Inc. (KYMR)Equibles does not estimate personal net worth.
Get an email with a short summary when Beam Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get BEAM alertsAbout John Maraganore
John Maraganore is recorded as Board Member at Beam Therapeutics Inc. (BEAM) and Board Member at Kymera Therapeutics, Inc. (KYMR) since January 1, 2022. The newest filing on record that lists John Maraganore as Board Member at Beam Therapeutics Inc. (BEAM) is dated April 17, 2026. The newest filing on record that lists John Maraganore as Board Member at Kymera Therapeutics, Inc. (KYMR) is dated April 29, 2026. John Maraganore was last confirmed as CEO at Alnylam Pharmaceuticals, Inc. (ALNY) in a filing dated April 5, 2022. The proxy statement of Alnylam Pharmaceuticals, Inc. reports total compensation of $10,176,685 for John Maraganore in fiscal 2021, including a base salary of $948,500. Disclosed compensation is on record for 5 fiscal years. John Maraganore has spoken on 7 earnings calls across 1 company, most recently for Alnylam Pharmaceuticals, Inc. on October 28, 2021. Beam Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Kymera Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls John Maraganore spoke on are classified in the Healthcare sector. Other leadership on record at Beam Therapeutics Inc. includes John Evans (CEO, Chief Accounting Officer and Board Member), Sravan Emany (CFO), Sravan K. Emany (CFO) and 6 others.
John Maraganore on recent calls
“In the third quarter and recent period, we made continued progress bringing our commercial RNAi therapeutics to patients around the world.”
“In the second quarter and recent period, we made tremendous progress bringing RNAi therapeutics to patients around the world with our commercial, medical, and R&D efforts while delivering solid financial performance.”
“2021 is off to a great start for Alnylam with four approved RNAi therapeutics now helping patients around the world and more in our pipeline poised to do the same in the coming years.”
“Despite the challenges we all faced in 2020 with the COVID-19 pandemic, Alnylam had one of its strongest years ever as a successful global commercial organization with a highly productive R&D platform.”
“We believe the third quarter and recent period highlight the tremendous progress Alnylam has made as a global commercial organization with a highly productive R&D platform.”
Affiliation history
-
Current
2022-01-01–present
Last confirmed April 29, 2026
-
Current
Start not stated–present
Last confirmed April 17, 2026
-
Start not stated–2022-04-05
Last confirmed by a filing; no departure on record
Company network
Biotechnology · Healthcare
Board Member
2022-01-01–present
Leadership on record at Beam Therapeutics Inc.
- John Evans CEO, Chief Accounting Officer, Board Member
- Sravan Emany CFO
- Sravan K. Emany CFO
- Chirfi Guindo Board Member
- Christi Shaw Board Member
- Graham Cooper Board Member
- John Maraganore, Ph.D. Board Member
- Kathleen Walsh Board Member
- Mark Fishman Board Member
Leadership on record at Kymera Therapeutics, Inc.
- Bruce Jacobs CFO
- Jeremy Chadwick COO
- Jeremy Chadwick, Ph.D. COO
- Brian R. Adams General Counsel
- Brian R. Adams, J.D. General Counsel
- Bruce Booth Board Member
- Elena Ridloff Board Member
- Felix J. Baker, Ph.D. Board Member
- Gorjan Hrustanovic, Ph.D. Board Member
- Nello Mainolfi Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Alnylam Pharmaceuticals, Inc. (ALNY) | Former ChiefExecutive Officer (principal executive officer) | $948,500 | $10,176,685 |
| 2020 | Alnylam Pharmaceuticals, Inc. (ALNY) | Former ChiefExecutive Officer (principal executive officer) | $946,200 | $7,818,164 |
| 2019 | Alnylam Pharmaceuticals, Inc. (ALNY) | Former ChiefExecutive Officer (principal executive officer) | $845,000 | $7,317,856 |
| 2018 | Alnylam Pharmaceuticals, Inc. (ALNY) | Chief Executive Officer(principal executive officer) | $800,000 | $5,089,269 |
| 2017 | Alnylam Pharmaceuticals, Inc. (ALNY) | Ph.D. Chief ExecutiveOfficer (principal executive officer) | $753,548 | $1,417,394 |